Stifel analyst Bradley Canino raised the firm’s price target on Affimed to $5 from $1 and keeps a Hold rating on the shares following the recent stock split. Affimed narrowed program updates to Q2 during Friday’s call, saying enrollment for cohorts 3 and 4 for acimtamig+AB-101will begin mid-April, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD: